/
Navigation
Chronicles
Browse all articles
Explore
Semantic exploration
Research
Entity momentum
Nexus
Correlations & relationships
Story Arc
Topic evolution
Drift Map
Semantic trajectory animation
Posts
Analysis & commentary
Pulse API
Tech news intelligence API
Browse
Entities
Companies, people, products, technologies
Domains
Browse by publication source
Handles
Browse by social media handle
Detection
Concept Search
Semantic similarity search
High Impact Stories
Top coverage by position
Sentiment Analysis
Positive/negative coverage
Anomaly Detection
Unusual coverage patterns
Analysis
Rivalry Report
Compare two entities head-to-head
Semantic Pivots
Narrative discontinuities
Crisis Response
Event recovery patterns
Connected
Search: /
Command: ⌘K
Embeddings: large
Company

FDA

85 articles decelerating

In 2026, an FDA fast track for digital-health AI and Kintsugi’s clearance failure made the agency a central gatekeeper for healthcare software.

Who they are

FDA appears in this coverage as the U.S. regulator whose clearances, authorizations, trial approvals and enforcement role determine whether consumer devices, clinical software and brain-computer interfaces can move into healthcare use. Its recurring role is especially prominent around Apple, Samsung, Google, Neuralink and smaller digital-health developers.

The recent arc

Coverage intensified in the 2024 wearable-health cycle, led by Samsung’s authorization for Galaxy Watch sleep-apnea detection and the FDA’s approval of Apple’s sleep-apnea detection across recent Apple Watch models. Apple’s AirPods Pro 2 hearing-aid feature then became a landmark story: TechCrunch described it as the first over-the-counter hearing-aid software device.

The tension

The coverage circles a persistent trade-off between accelerating health-tech innovation and preserving a credible clinical gatekeeping function. Apple, Samsung and Google have sought regulatory validation for increasingly medical smartwatch features, while Neuralink and Paradromics depend on authorization to test brain implants; Kintsugi’s shutdown after failing to obtain clearance shows that the same threshold can constrain AI-health startups.

Why it matters

If the fast-track approach to digital health continues, FDA decisions could increasingly shape which AI tools become embedded in healthcare and consumer devices, not merely which conventional medical hardware reaches patients. The unresolved question in the coverage is whether quicker pathways can widen access without weakening the evidentiary standards that distinguish medical claims from general-purpose technology.

FDA has appeared in 85 articles since 2015-03. Coverage peaked in 2024Q2 with 7 articles. Frequently mentioned alongside Apple, the Apple Watch, The Food and Drug Administration, Neuralink.

Articles
85
mentions
Velocity
-50.0%
growth rate
Acceleration
-1.500
velocity change
Sources
34
publications

Coverage Timeline

2026-07-04
Financial Times 1 related

An interview with Sriram Krishnan, who says “there will not be an FDA for AI” under Trump, blames the AI backlash on the industry's “doomer” messaging, and more

Sriram Krishnan tells the FT the president is against a centralised regulator as AI backlash grows

2026-07-03
Financial Times

An interview with Sriram Krishnan, who says “there will not be an FDA for AI” under Trump, blames the AI backlash on the industry's “doomer” messaging, and more

Sriram Krishnan tells the FT the president is against a centralised regulator as AI backlash grows

2026-06-07
Washington Post 2 related

Inside the Trump admin's push to integrate AI into the healthcare system, including an FDA regulatory fast track for digital health tech like AI chatbots

The administration is laying the groundwork for chatbots that can diagnose illness and prescribe medicine, but physicians say AI can introduce more problems.

2026-06-06
Washington Post 3 related

Inside the Trump admin's push to integrate AI into the healthcare system, including an FDA regulatory fast track for digital health tech like AI chatbots

The administration is laying the groundwork for chatbots that can diagnose illness and prescribe medicine, but physicians say AI can introduce more problems.

2026-04-03
The Verge 3 related

Mental health startup Kintsugi is shutting down and open sourcing its AI tech for detecting depression and anxiety from speech, after not securing FDA clearance

2026-04-02
The Verge 3 related

Mental health startup Kintsugi is shutting down and open-sourcing its AI tech to detect depression and anxiety, after failing to secure FDA clearance

Instead, a mental health startup shut down and open-sourced its tech. … For the past seven years, the California-based startup Kintsugi …

2025-11-20
Wired 1 related

Paradromics says it received FDA approval for a human trial of its Connexus brain implant, aimed at restoring speech to those with severe motor impairments

The Austin-based startup will test its high-bandwidth device to help restore speech in people with extremely limited movement.

2025-10-16
MIT Technology Review

How AI-powered tools like PainChek, an app that scans a person's face for tiny muscle movements, are helping health care providers better assess patients' pain

For years at Orchard Care Homes, a 23‑facility dementia-care chain in northern England, Cheryl Baird watched nurses fill … X: @deenamousa , @deenamousa , @deenamousa , @deenamousa , and @deenamousa Bl...

2025-09-10
The Verge 11 related

Apple Watch's hypertension notifications and sleep score will come to some older models with watchOS 26; Apple expects FDA clearance for the notifications soon

New hypertension notifications are coming to the Watch Series 9 and up. … Apple just announced a bunch of new health-tracking …

2025-07-31
Tech.eu 6 related

Oxford-based Ultromics, which has developed the first FDA-cleared, Medicare-reimbursed AI tools for cardiology diagnostics, raised a $55M Series C

The funding will accelerate Ultromics' mission to advance heart disease detection and scale EchoGo®, its AI platform for earlier, more accurate diagnoses.

Loading articles...

Quarterly Coverage

Top Sources

Narrative

Key Moments

2024Q2developer -5pts; consumer +25pts; funding +20pts
2024Q3consumer -20pts; funding +20pts
2025Q2developer +13pts; consumer -80pts; funding -23pts

Relationships

Loading graph...